Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 220-228 , February 2008

High Busulfan Exposure Is Associated with Worse Outcomes in a Daily i.v. Busulfan and Fludarabine Allogeneic Transplant Regimen

  • Michelle Geddes

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • Corresponding Author InformationCorrespondence and reprint requests: Michelle Geddes, MD, Foothills Medical Centre 601 South Tower, 1403-29 Street NW, Calgary, Alberta T2N 2T9, Canada.
    • ,
  • S. Bill Kangarloo

      Affiliations

    • Tom Baker Cancer Centre, Calgary, Canada
    • ,
  • Farrukh Naveed

      Affiliations

    • Tom Baker Cancer Centre, Calgary, Canada
    • ,
  • Diana Quinlan

      Affiliations

    • Tom Baker Cancer Centre, Calgary, Canada
    • ,
  • M. Ahsan Chaudhry

      Affiliations

    • Tom Baker Cancer Centre, Calgary, Canada
    • ,
  • Douglas Stewart

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • ,
  • M. Lynn Savoie

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • ,
  • Nizar J. Bahlis

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • ,
  • Christopher Brown

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • ,
  • Jan Storek

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada
    • ,
  • Borje S. Andersson

      Affiliations

    • Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, Texas
    • ,
  • James A. Russell

      Affiliations

    • Division of Hematology and Hematologic Malignancy, University of Calgary, Calgary, Canada

Received 7 May 2007 ,Accepted 29 October 2007.

References 

  1. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with venoocclusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55–61
  2. Hassan M, A-berg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991;28:130–134
  3. Vassal G. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls. Anticancer Res. 1994;14:2363–2370
  4. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood. 1990;75:1723–1727
  5. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood. 1999;12:4436–4440
  6. Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJ, Williamson S. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant. 1986;1:201–208
  7. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42
  8. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant. 2000;25:925–930
  9. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  10. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203–6207
  11. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201–1207
  12. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001;28:1013–1018
  13. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–826
  14. Takama H, Tanaka H, Nakashima D, Ueda R, Takaue Y. Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006;37:345–351
  15. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–485
  16. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol. 2006;57:191–198
  17. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (i.v. BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant. 2002;8:145–154
  18. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007;13:56–64
  19. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103
  20. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468–476
  21. Copelan EA, Biggs Js, Avalos BR, et al. Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol. 1992;10:237–242
  22. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–864
  23. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036–2043
  24. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood. 1999;93:2196–2201
  25. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  26. Heggie JR, Wu M, Burns RB, et al. Validation of a high-performance liquid chromatographic assay method for pharmacokinetic evaluation of busulfan. J Chromatogr B Biomed Sci Appl. 1997;692:437–444
  27. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562–1568
  28. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–783
  29. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood. 2003;102:31–35
  30. Savoie ML, Balogh A, Chaudhry A, et al. Total body irradiation (TBI) added to fludarabine/busulfan/antithymocyte globulin (FLUBUP/ATG) conditioning increases overall survival and relapse-free survival in patients with acute myelogenous leukemia (AML) receiving allogeneic stem cell transplant. Blood. 2006;108,855a
  31. Russell JA, Savoie ML, Balogh A, et al. Allogeneic transplant for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 cGy total body irradiation and thymoglobulin. Biol Blood Marrow Transplant. 2007;13:814–821
  32. Williams CB, Day S, Reed M, et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2004;10:614–623
  33. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:486–492
  34. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42
  35. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol. 1993;20:18–25quiz 26
  36. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001;28:743–751
  37. Deeg HJ, Schulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188–1194
  38. Tran H, Petropoulos D, Worth L, et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:805–812
  39. Kangarloo SB, Naveed F, Quinlan D, et al. Implementation and results of a test dose programme for individualized dosing of once daily intravenous Busulfan with fludarabine in allogeneic stem cell transplantation conditioning. Bone Marrow Transplant. 2007;39(S1):P592a

PII: S1083-8791(07)00557-5

doi: 10.1016/j.bbmt.2007.10.028

Biology of Blood and Marrow Transplantation
Volume 14, Issue 2 , Pages 220-228 , February 2008

Article Tools

* Image Usage & Resolution